Logo Image
|Articles|April 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Partnerships: Bargaining Biotechs

Author(s)Kevin Gopal

Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.

Articles in this issue

over 25 years ago

Internet DTC - Minding Your P's & Q's

over 25 years ago

Regulation: Two-Track Plan

over 25 years ago

Policy: Tectonic Shift

over 25 years ago

Liberated?

over 25 years ago

A Matter of Taste

over 25 years ago

Pediatric Mandate

over 25 years ago

Genentech's Passion for Patients

over 25 years ago

Regulation: OK After All

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more